Generic Accupril Availability

Accupril is a brand name of quinapril, approved by the FDA in the following formulation(s):

ACCUPRIL (quinapril hydrochloride - tablet;oral)

  • Manufacturer: PFIZER PHARMS
    Approval date: November 19, 1991
    Strength(s): EQ 5MG BASE [AB], EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 40MG BASE [RLD] [AB]

Has a generic version of Accupril been approved?

A generic version of Accupril has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Accupril and have been approved by the FDA:

quinapril hydrochloride tablet;oral

  • Manufacturer: AUROBINDO PHARMA LTD
    Approval date: April 29, 2013
    Strength(s): EQ 5MG BASE [AB], EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 40MG BASE [AB]
  • Manufacturer: INVAGEN PHARMS
    Approval date: August 24, 2007
    Strength(s): EQ 5MG BASE [AB], EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 40MG BASE [AB]
  • Manufacturer: LUPIN
    Approval date: June 20, 2006
    Strength(s): EQ 5MG BASE [AB], EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 40MG BASE [AB]
  • Manufacturer: MYLAN
    Approval date: December 23, 2004
    Strength(s): EQ 5MG BASE [AB], EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 40MG BASE [AB]
  • Manufacturer: RANBAXY
    Approval date: December 15, 2004
    Strength(s): EQ 5MG BASE [AB], EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 40MG BASE [AB]
  • Manufacturer: SUN PHARM INDS LTD
    Approval date: June 18, 2009
    Strength(s): EQ 5MG BASE [AB], EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 40MG BASE [AB]
  • Manufacturer: TEVA
    Approval date: August 24, 2007
    Strength(s): EQ 5MG BASE [AB], EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 40MG BASE [AB]
  • Manufacturer: WATSON LABS FLORIDA
    Approval date: January 14, 2005
    Strength(s): EQ 5MG BASE [AB], EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 40MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Accupril. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Method of treating cardiac insufficiency
    Patent 5,684,016
    Issued: November 4, 1997
    Inventor(s): Henning; Rainer & Urbach; Hansjorg & Teetz; Volker & Geiger; Rolf & Scholkens; Bernward
    Assignee(s): Hoechst Aktiengesellschaft
    The invention relates to a method of treating cardiac insufficiency by using compounds of the formula I ##STR1## in which n is 1 or 2, R, R.sup.1, R.sup.2 and R.sup.3 are identical or different and each denote hydrogen or an organic radical and R.sup.4 and R.sup.5, together with the atoms carrying them, form a mono-, bi- or tri-cyclic heterocyclic ring system. The invention furthermore relates to compounds of the formula I and agents containing these for use in the treatment of the abovementioned disease.
    Patent expiration dates:
    • November 4, 2014
      ✓ 
      Patent use: METHOD OF TREATING CONGESTIVE HEART FAILURE
    • May 4, 2015
      ✓ 
      Pediatric exclusivity

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide
(web4)